Drug release testing methods of polymeric particulate drug formulations

2013 ◽  
Vol 43 (4) ◽  
pp. 259-266 ◽  
Author(s):  
Sarmila Amatya ◽  
Eun Ji Park ◽  
Jong Hoon Park ◽  
Joon Sik Kim ◽  
Eunyoung Seol ◽  
...  
Author(s):  
Anna Externbrink ◽  
Karin Eggenreich ◽  
Simone Eder ◽  
Stefan Mohr ◽  
Klaus Nickisch ◽  
...  

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1313
Author(s):  
Yejin Kim ◽  
Eun Ji Park ◽  
Tae Wan Kim ◽  
Dong Hee Na

Biopolymeric microparticles have been widely used for long-term release formulations of short half-life chemicals or synthetic peptides. Characterization of the drug release from microparticles is important to ensure product quality and desired pharmacological effect. However, there is no official method for long-term release parenteral dosage forms. Much work has been done to develop methods for in vitro drug release testing, generally grouped into three major categories: sample and separate, dialysis membrane, and continuous flow (flow-through cell) methods. In vitro drug release testing also plays an important role in providing insight into the in vivo performance of a product. In vitro release test with in vivo relevance can reduce the cost of conducting in vivo studies and accelerate drug product development. Therefore, investigation of the in vitro–in vivo correlation (IVIVC) is increasingly becoming an essential part of particulate formulation development. This review summarizes the principles of the in vitro release testing methods of biopolymeric particulate system with the recent research articles and discusses their characteristics including IVIVC, accelerated release testing methods, and stability of encapsulated drugs.


Author(s):  
Shaolong He ◽  
Jette Jacobsen ◽  
Carsten Uhd Nielsen ◽  
Natalja Genina ◽  
Jesper Østergaard ◽  
...  

Author(s):  
Michael J. Rathbone ◽  
Jingjian Shen ◽  
Colin R. Ogle ◽  
Shane Burggraaf ◽  
Craig R. Bunt

2014 ◽  
Vol 475 (1-2) ◽  
pp. 393-400 ◽  
Author(s):  
Jacqueline M. Morais ◽  
Diane J. Burgess

Biomaterials ◽  
1998 ◽  
Vol 19 (7-9) ◽  
pp. 817-819 ◽  
Author(s):  
Mansho Itokazu ◽  
Wenyi Yang ◽  
Takaaki Aoki ◽  
Akira Ohara ◽  
Naoki Kato

1986 ◽  
Vol 58 (11) ◽  
pp. 2316-2320 ◽  
Author(s):  
R. J. Eckstein ◽  
Grover D. Owens ◽  
M. A. Baim ◽  
D. A. Hudson
Keyword(s):  

2020 ◽  
Vol 88 (1) ◽  
pp. 6
Author(s):  
Potiwa Purazi ◽  
Seeprarani Rath ◽  
Ashmita Ramanah ◽  
Isadore Kanfer

In vitro release testing (IVRT) provides an efficient method for the evaluation of drug release from semi-solid formulations. The aim of this research was to develop and validate a discriminatory IVRT system using vertical diffusion cells (VDCs) to assess generic topical products containing miconazole nitrate (MCZ). A comprehensive approach addressing all essential suitability criteria supporting the reliability of IVRT results was applied. These include mechanical validation of the VDCs, a performance verification test (PVT), validation of the analytical method (HPLC) used to quantify the drug release and validation of the IVRT method to confirm its precision, reproducibility, discriminatory ability, and robustness. Two marketed generic products were tested and assessed in accordance with the acceptance criteria for “sameness” in the FDA’s SUPAC-SS guidance which requires that the 90% confidence interval (CI) should fall within the limits of 75%–133.33%. One product was found to be in vitro equivalent to the reference product whereas the other was not. The results confirmed the suitability of the IVRT method to accurately measure the release of MCZ from topical cream products and, importantly, demonstrated the necessary discriminatory ability to assess “sameness”/differences of dermatological creams containing MCZ. Furthermore, the developed IVRT method was able to detect differences between formulations, which may be attributed to qualitative (Q1) and quantitative (Q2) properties and the microstructure and arrangement of matter (Q3).


Sign in / Sign up

Export Citation Format

Share Document